Rational design of small molecules as vaccine adjuvants

Multifunctional PLGA-Based Nanoparticles Encapsulating Simultaneously Hydrophilic Antigen and Hydrophobic Immunomodulator for Mucosal Immunization

(2013) Charlotte Primard et al.   MOLECULAR PHARMACEUTICS

Human Vaccines & Immunotherapeutics: News

(2013) Eva M. Riedmann   Human Vaccines & Immunotherapeutics

Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses

(2012) S.B. Rizwan et al.   JOURNAL OF CONTROLLED RELEASE

The mechanism of action of MF59 – An innately attractive adjuvant formulation

(2012) D.T. O’Hagan et al.   VACCINE

Development of an Automated, High-Throughput Bactericidal Assay That Measures Cellular Respiration as a Survival Readout for Neisseria meningitidis

(2011) Puiying A. Mak et al.   Clinical and Vaccine Immunology

A Point Mutation in the Amino Terminus of TLR7 Abolishes Signaling without Affecting Ligand Binding

(2011) Carlo Iavarone et al.   JOURNAL OF IMMUNOLOGY

New adjuvants for human vaccines

(2010) M Lamine Mbow et al.   CURRENT OPINION IN IMMUNOLOGY

Genetic shifts ofNeisseria meningitidisserogroup B antigens and the quest for a broadly cross-protective vaccine

(2010) Xilian Bai et al.   Expert Review of Vaccines

Identification of Novel Synthetic Toll-like Receptor 2 Agonists by High Throughput Screening

(2010) Yue Guan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pemphigus-like lesions induced by imiquimod

(2009) A. Bauza et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Fast Tracking the Vaccine Licensure Process to Control an Epidemic of Serogroup B Meningococcal Disease in New Zealand

(2009) Diana Lennon et al.   CLINICAL INFECTIOUS DISEASES

The path to a successful vaccine adjuvant – ‘The long and winding road’

(2009) Derek T. O’Hagan et al.   DRUG DISCOVERY TODAY

TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity

(2009) Teresa R. Johnson et al.   VACCINE

A phase II dose-ranging study of topical resiquimod to treat actinic keratosis

(2008) R.-M. Szeimies et al.   BRITISH JOURNAL OF DERMATOLOGY

Interlaboratory Comparison of Results of an Anthrax Lethal Toxin Neutralization Assay for Assessment of Functional Antibodies in Multiple Species

(2008) K. S. Omland et al.   Clinical and Vaccine Immunology

Clinical investigations of Toll-like receptor agonists

(2008) Thomas Meyer et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA